Company Filing History:
2 out of 975 
1 out of 516 
1 out of 8 
Years Active: 2018-2022
Title: Innovations by Bonnie LaFleur in Cancer Research
Introduction
Bonnie LaFleur is an accomplished inventor based in Tucson, AZ (US). She has made significant contributions to the field of cancer research, particularly in the classification and risk stratification of diffuse large B-cell lymphoma (DLBCL). With a total of 4 patents, her work has the potential to greatly enhance diagnostic and therapeutic approaches in oncology.
Latest Patents
One of her latest patents is titled "Methods for subtyping diffuse large B-cell lymphoma (DLBCL)." This innovation focuses on classifying subtypes of DLBCL and utilizing the classification results for diagnosis, prognosis, and therapy selection. The classifier developed can effectively categorize subtypes of DLBCL, providing valuable insights for medical practices and improving outcomes for DLBCL patients. Additionally, she has developed arrays and kits designed to measure the expression of DLBCL signature genes.
Another notable patent is "Cancer risk stratification based on histopathological tissue slide analysis." This patent presents systems and computer-implemented methods that offer reliable risk stratification for early-stage cancer patients. By predicting a patient's recurrence risk, the system categorizes patients into high or low-risk groups. The process involves automatic analysis of serial sections of cancerous tissue using a digital pathology system, calculating scores for the sections, and applying a Cox proportional hazards regression model for patient stratification.
Career Highlights
Bonnie LaFleur has worked with prestigious organizations such as the University of Arizona and Ventana Medical Systems, Inc. Her experience in these institutions has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Throughout her career, Bonnie has collaborated with notable colleagues, including Eugene W. Gerner and Edwin Paz. These partnerships have further enriched her research and innovations in cancer diagnostics.
Conclusion
Bonnie LaFleur's contributions to cancer research through her innovative patents demonstrate her commitment to improving patient outcomes. Her work in classifying DLBCL and risk stratification is paving the way for advancements in medical practices.